Evaluation of the Pharmacokinetics, Safety and Tolerability of a Single Dose of GLPG2737 Administered as Oral Suspension in Male Subjects With Cystic Fibrosis
Latest Information Update: 04 Nov 2021
At a glance
- Drugs GLPG 2737 (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Galapagos NV
Most Recent Events
- 07 Mar 2018 New trial record